News & Press
See all
News & Press
6. November, 2020
Approval for IPO listing
Cessatech A/S today announces that Spotlight Stock Market’s listing committee has approved Cessatech’s application...
News & Press
18. August, 2020
Strong profiles to the Board
The Board has a wide experience from the entire value chain, which is a strong asset for Cessatech and its future aspirations
News & Press
26. May, 2020
Copenhagen Science
Novel painkiller is remarkably close to market, and the team is now expanding its business development activities
News & Press
14. December, 2019
TV2 Nyhederne
En nyudviklet næsespray, er dagens store nyhed i TV2 Nyhederne - udviklet på Rigshospitalet af ledende eksperter
Facts about Children
See all
Facts
31. August, 2020
DR.dk focus
Kan give voldsomme bivirkninger, når børn og ældre får medicin, der ikke er godkendt til dem...
Facts
1. May, 2020
High off-label use
Studies are still needed to determine the safety and efficacy of drugs that lack FDA labeling for this vulnerable patient population. Drugs were administered off-label...
Facts
1. May, 2020
Small adults?
Children differ pharmacokinetically from adults, and medication for adults cannot simply be administered in smaller doses
Experience
Proven track-record within drug development and product launches, in Europe, US and Asia.
The executive management team and the Board of Directors have a proven track-record within drug development, paediatric analgesic research, product launches and capital raising across all major markets.
Team
Lead Asset
CT001 – Nasal spray
Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful experience.
See details